| P50 | author | Steven Libutti | Q7614982 |
| | Thomas J Quinn | Q45310205 |
| P2093 | author name string | Wade Koba | |
| | David T Hughes | |
| | Ziqiang Yuan | |
| | Rula Geha | |
| | Herbert A Schmid | |
| | Asha Adem | |
| | Eugene Fine | |
| | Chakravarthy Vrikshajanani | |
| P2860 | cites work | Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study | Q79260198 |
| | Medical treatment of benign insulinoma using octreotide LAR: a case report | Q79379722 |
| | Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas | Q83118235 |
| | Neuroendocrine tumors of the pancreas | Q83762285 |
| | Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases | Q28290384 |
| | Somatostatin analogs - from new molecules to new applications | Q35938751 |
| | Diazoxide treatment for insulinoma: a national UK survey | Q36728183 |
| | Well-differentiated pancreatic tumor/carcinoma: insulinoma | Q36741120 |
| | One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States | Q37195528 |
| | Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. | Q37429020 |
| | Multiple endocrine neoplasia type 1: clinical manifestations and management | Q37643633 |
| | Clinical review 72: diagnosis and management of functioning islet cell tumors | Q40456829 |
| | Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line | Q42848672 |
| | Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial | Q43089850 |
| | A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients | Q44757106 |
| | SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action | Q48897339 |
| | Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia. | Q51539178 |
| | Pancreatic endocrine tumors | Q57794113 |
| | SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas | Q59122469 |
| | Diazoxide in the management of patients with insulinoma | Q70147196 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pasireotide | Q3896970 |
| | knockout mouse | Q1364740 |
| | multiple endocrine neoplasia | Q1553018 |
| | multiple endocrine neoplasia type 1 | Q3347154 |
| | pasireotide diaspartate | Q21547171 |
| P304 | page(s) | 1068-1077 | |
| P577 | publication date | 2012-10-24 | |
| P1433 | published in | Surgery | Q15731526 |
| P1476 | title | Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model | |
| P478 | volume | 152 | |